Thiopurine S-methyltransferase gene polymorphism in Chilean blood donors;Polimorfismo del gen de la tiopurina S-metiltransferasa en donantes de sangre de un hospital universitario

Revista Medica de Chile

Volumn 137, Issue 2, 2009, Pages 185-192

  Álvarez L, Luis ^a   Venegas S, Mauricio ^a   Larrondo L, Milton ^b   Becerra B, Natalia ^a   Castro L, Ariel ^c   Quera P, Rodrigo ^a,d  

^a Departamento de Medicina Interna   (Chile)

^b Banco de Sangre ^*  (Chile)

^c HOSPITAL CLÍNICO UNIVERSIDAD DE CHILE   (Chile)

^d CLÍNICA LAS CONDES   (Chile)

Author keywords

Blood donors; Genetic polymorphism; Methyltransferases

Indexed keywords

METHYLTRANSFERASE; THIOPURINE METHYLTRANSFERASE;

ADULT; AGED; ALLELE; ARTICLE; BLOOD DONOR; CHILE; ETHNOLOGY; FEMALE; GENE FREQUENCY; GENETIC HETEROGENEITY; GENETIC MARKER; GENETIC POLYMORPHISM; GENETICS; HETEROZYGOTE; HUMAN; MALE; MIDDLE AGED; PHENOTYPE;

ADULT; AGED; ALLELES; BLOOD DONORS; CHILE; FEMALE; GENE FREQUENCY; GENETIC HETEROGENEITY; GENETIC MARKERS; HETEROZYGOTE; HUMANS; MALE; METHYLTRANSFERASES; MIDDLE AGED; PHENOTYPE; POLYMORPHISM, GENETIC; YOUNG ADULT;

EID: 67650097604     PISSN: 00349887     EISSN: 07176163     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Krynetski EY, Tai HL, Yates CR, Fessing MY, Loennechen T, Schuetz JD, et al. Genetic polymorphism of thiopurine S-methyltransferase: clinical importance and molecular mechanisms. Pharmacogenetics 1996; 6: 279-90.
2. Milanese C, la Mantia L, Salmaggi A, Eoli M. A double blind study of azathioprine efficacy in multiple sclerosis: final report. J Neurol 1993; 240: 295-8.
3. Kerstens PJ, Stolk JN, Boerbooms AM, Lambooy LH, de Graaf R, de Abreu RA. Purine enzymes in rheumatoid arthritis: possible association with response to azathioprine. A pilot study. Ann Rheum Dis 1994; 53: 608-11.
4. Heneghan MA, Allan ML, Bornstein JD, Muir A, Tendler DA. Utility of thiopurine methyltransferase genotyping and phenotyping, and measurement of azathioprine metabolites in the management of patients with autoimmune hepatitis. J Hepatol 2006; 45: 584-91.
5. Derijks LJJ, Gilissen LPL, Hooymans PM, Hommes DW. Review article: thiopurines in inflammatory bowel disease. Aliment Pharmacol Ther 2006; 24: 715-29.
6. Lennard L, Lilleyman JS, van Loon J, Weinshilboum RM. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 1990; 336: 225-9.
7. Hollander AA, van Saase JL, Kootte AM, van Dorp WT, van Bockel HJ, van Es LA, et al. Beneficial effects of conversion from cyclosporine to azathioprine after kidney transplantation. Lancet 1995; 345: 610-4.
8. Lennard L, van Loon JA, Lilleyman JS, Weinshilboum RM. Thiopurine pharmacogenetics in leukemia: correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations. Clin Pharmacol Ther 1987; 41: 18-25.
9. Szumlanski C, Otterness D, Her C, Lee D, Brandriff B, Kelsell D, et al. Thiopurine methyltransferase pharmacogenetics: human gene cloning and characterization of a common polymorphism. DNA Cell Biol 1996; 15: 17-30.
10. Seki T, Tanaka T, Nakamura Y. Genomic structure and multiple single-nucleotide polymorphisms (SNPs) of the thiopurine S-methyltransferase (TPMT) gene. J Hum Genet 2000; 45: 299-302.
11. Salavaggione OE, Wang L, Wiepert M, Yee VC, Weinshilboum RM. Thiopurine S-methyltransferase pharmacogenetics: variant allele functional and comparative genomics. Pharmacogenet Genomics 2005; 11: 801-15.
12. Schaeffler E, Fischer C, Brockmeier D, Wernet D, Moerike K, Eichelbaum M, et al. Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants. Pharmacogenetics 2004; 7: 407-17.
13. *22) - association with decreased enzyme function. Hum Mutat 2006; 27: 976.
14. Wang L, Weinshilboum R. Thiopurine S-methyltransferase pharmacogenetics: insights, challenges and future directions. Oncogene 2006; 25: 1629-38.
15. Larovere LE, Dodelson de Kremer R, Lambooy LHJ, de Abreu RA. Genetic polymorphism of thiopurine Smethyltransferase in Argentina. Ann Clin Biochem 2003; 40: 388-93.
16. Isaza C, Henao J, López AM, Cacabelos R. Allelic variants of the thiopurine methyltransferase (TMPT) gene in the Colombian population. Methods Fin Exp Clin Pharmacol 2003; 25: 423-9.
17. Lu HF, Shih MC, Hsueh SC, Chen CM, Chang JY, Chang JG. Molecular analysis of the thiopurine S-methyltransferase alleles in Bolivians and Tibetans. J Clin Pharm Ther 2005; 30: 491-6.
18. Boson WL, Romano-Silva MA, Correa H, Falcao RP, Teixeira-Vidigal PV, de Marco L. Thiopurine methyltransferase polymorphisms in a Brazilian population. Pharmacogenomics J 2003; 3: 178-82.
19. Yates CR, Krynetski E, Loennechen T, Fessing M, Tai HL, Pui CH, et al. Molecular diagnosis of thiopurine S-Methyltransferase deficiency: Genetic basis for azathioprine and mercaptopurine intolerance. Ann Inter Med 1997; 126: 608-14.
20. Loennechen T, Utsi E, Hartz I, Lysaa R, Kildalsen H, Aarbakke J. Detection of one single mutation predicts thiopurine S-methyltransferase activity in a population of Saami in northern Norway. Clin Pharmacol Ther 2001; 70: 183-8.
21. Campillo FL. Estudio de los Grupos Sanguíneos en la Población Española. Comunicación de la Real Academia de Medicina. Tomo XCII de los Anales. Madrid: Cuaderno Tercero 1976.
22. Matson A, Sutton E, Etcheverry R, Swanson J, Robinson A. Distribution of hereditary blood groups among Indians in South America. Am J Phys Anthropol 1967; 27: 157-94.
23. Llop E, Rothhammer F. A note on the presence of blood groups A y B in pre-Columbian South America. Am J Phys Anthropol 1988; 75: 107-11.
24. Sahasranaman S, Howard D, Roy S. Clinical pharmacology and pharmacogenetics of thiopurines. Eur J Clin Pharmacol 2008; 64: 753-67.
25. Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease. A 30 year review. Gut 2000; 50: 485-9.
26. Jorquera A, Selman C, Vollrath V, Solari S, Álvarez M. Fenotipo y genotipo de la tiopurina metiltransferasa (TPMT) en población chilena. Gastr Latinoam 2006; 17: 447 (Abstract).
27. Krinetski EY, Schuetz JD, Gapin AJ, Pui CH, Relling MV, Evans WE. A single mutation leading to loss of catalytic activity in human thiopurine s-methyltranferase. Proc Natl Acd Sci USA 1995; 92: 949-53.
28. Tai HL, Krinetski EY, Yates CR, Loennechen T, Fessing M, Krynetskaia NF et al. Thiopurine S-methyltranferase deficiency: two nucleotidee transitions define the most prevalent mutant allele associated with loss of catalytic activity in caucasians. Am J Hum Genet 1996; 58: 694-702.
29. Evans WE, Hon YY, Bomgaars L, Coutre S, Holdsworth M, Janco R, et al. Preponderance of thiopurine Smethyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. J Clin Oncol 2001; 19: 2293-301.
30. McLeod HL, Silva C. The thiopurine S-methyltransferase gene locus-implications for clinical pharmacogenomics. Pharmacogenomics 2002; 3: 89-98.
31. Krynetski EY, Evans WE. Genetic polymorphism of thiopurine S-methyltransferase: molecular mechanism and clinical importance. Pharmacology 2000; 61: 136-46.
32. Schaeffler E, Lang T, Zanger UM, Eichelbaum M, Schwab M. High-throughput genotyping of thiopurine S-methyltransferase by denaturing HPLC. Clin Chem 2001; 47: 548-55.
33. Weinshilboum R. Thiopurine pharmacogenetics: clinical and molecular studies of thiopurine methyltransferase. Drug Metab Dispos 2001; 29: 601-5.
34. Lennard L. TMPT in the treatment of Crohn's disease with azathioprine. Gut 2002; 51: 143-6.
35. Reuther LO, Sonne J, Larsen N, Dahlerup JF, Thomsen OO, Schmiegelow K. Thiopurine methyltransferase genotype distribution in patients with Crohn's disease. Aliment Pharmacol Ther 2003; 17: 65-8.
36. Kurzawski M, Gawronska-Szklarz B, Drozdzik M. Frequency distribution of thiopurine S-methyltransferase alleles in a Polish population. Ther Drug Monit 2004; 26: 541.5.
37. Rossi AM, Bianchi M, Guarnieri C, Barale R, Pacifici GM. Genotype-phenotype correlation for thiopurine S-methyltransferase in healthy Italian subjects. Eur J Clin Pharmacol 2001; 57: 51-4.
38. Cuffari C, Dassopoulos T, Turnbough L, Thompson RE, Bayless TM. Thiopurine methyltransferase activity influences clinical response to azathioprine in inflammatory bowel disease. Clin Gastroenterol Hepatol 2004; 2: 410-7.
39. Dubinsky MC, Lamothe S, Yang HY, Targan SR, Sinnett D, Theoret Y, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in flmmatory bowel disease. Gastroenterology 2000; 118: 705-13.
40. Gisbert JP, Luna M, Mate J, González-Guijarro L, Cara C, Pajares JM. Choice of azathioprine or 6-mercaptopurine dose based on thiopurine methyltransferase (TPMT) activity to avoid myelosuppression. A prospective study. Hepatogastroenterology 2006; 53: 399-404.
41. Bierau J, Lindhout M, Bakker JA. Pharmacogenetic significance of inosine triphosphatase. Pharmacogenomics 2007; 8: 1221-8.
42. van Dieren JM, Hansen BE, Kuipers EJ, Nieuwenhuis EE, van der Woude CJ. Meta-analysis: Inosine triphosphate pyrophosphatase polymorphisms and thiopurine toxicity in the treatment of inflammatory bowel disease. Aliment Pharmacol Ther 2007; 26: 643-52.